With the discovery of specific receptors that directly mediate the stimulatory activity of β-glucan on immune cells, such as Dectin-1 and Complement Receptor 3 (CR3), along with more recent research on how β-glucan mediates an innate memory response called “trained immunity,” and the use of β-glucan in combination with immunotherapy, there has been a reinvigorated wave of interest in β-glucan and anti-tumor responses [6]. Here, CRIPTO3 is linked to neoplasm.